Oral Answers to Questions

Richard Thomson Excerpts

Tuesday 17th November 2020 Commons Chamber

[Richard Thomson (Gordon) (SNP)]

What steps his Department is taking to ensure adequate supplies of personal protective equipment for (a) health, (b) social care and (c) other frontline services during the covid-19 outbreak.

[Martyn Day (Linlithgow and East Falkirk) (SNP)]

What steps his Department is taking to ensure adequate supplies of personal protective equipment for (a) health, (b) social care and (c) other frontline services during the covid-19 outbreak.

[The Parliamentary Under-Secretary of State for Health and Social Care (Jo Churchill)]

We have a four-month stockpile of all covid-critical PPE in place. Thanks must go to the tremendous contribution from UK manufacturers, including Honeywell in Motherwell in Scotland, which now meet 70% of our PPE needs. We have distributed 4.7 billion items, ensuring health and care providers and others have access to the critical protective equipment that they need to help keep everyone safe.

[Richard Thomson]

According to Treasury figures, the UK Government have spent £15 billion to date on PPE contracts, and the majority to date have been awarded without open tendering, often to those with connections to the governing party or to companies with no PPE experience at all. Does the Minister consider it is acceptable that, instead of that resource being used to protect frontline healthcare staff, so much of it has been squandered on millions of items that are absolutely unusable because they do not meet NHS standards, and how does she propose to restore this Government’s reputation for competence, probity and openness in the tendering process?

[Jo Churchill]

The global pandemic presented us with unprecedented challenges in securing the volumes of PPE required. We moved swiftly in order to make sure that we kept people safe. We procured goods and services, and worked with extreme urgency in accordance with procurement rules and Cabinet Office guidance. All offers were prioritised based on volume price, clinical acceptability and lead time. I am happy to reiterate: we have four months’ supply.